352 related articles for article (PubMed ID: 29369972)
1. mTOR Inhibition and Kidney Diseases.
Ma MKM; Yung S; Chan TM
Transplantation; 2018 Feb; 102(2S Suppl 1):S32-S40. PubMed ID: 29369972
[TBL] [Abstract][Full Text] [Related]
2. mTOR Inhibition and Clinical Transplantation: Kidney.
Flechner SM
Transplantation; 2018 Feb; 102(2S Suppl 1):S17-S18. PubMed ID: 28230636
[No Abstract] [Full Text] [Related]
3. mTOR Inhibition and Cardiovascular Diseases: Cardiac Hypertrophy.
Paoletti E
Transplantation; 2018 Feb; 102(2S Suppl 1):S41-S43. PubMed ID: 28230637
[TBL] [Abstract][Full Text] [Related]
4. mTOR Inhibition and Clinical Transplantation: Heart.
Zuckermann A; Osorio-Jaramillo E; Aliabadi-Zuckermann AZ
Transplantation; 2018 Feb; 102(2S Suppl 1):S27-S29. PubMed ID: 29369971
[TBL] [Abstract][Full Text] [Related]
5. mTOR Inhibition and Clinical Transplantation: Pancreas and Islet.
Berney T; Andres A; Toso C; Majno P; Squifflet JP
Transplantation; 2018 Feb; 102(2S Suppl 1):S30-S31. PubMed ID: 28230643
[TBL] [Abstract][Full Text] [Related]
6. mTOR Inhibition and Clinical Transplantation: Liver.
Nashan B
Transplantation; 2018 Feb; 102(2S Suppl 1):S19-S26. PubMed ID: 28230639
[TBL] [Abstract][Full Text] [Related]
7. The Long Journey of mTOR Inhibitors and the Long Path That Is Still Ahead.
Tedesco Silva H
Transplantation; 2018 Feb; 102(2S Suppl 1):S1-S2. PubMed ID: 29369969
[No Abstract] [Full Text] [Related]
8. Immunosuppressive minimization with mTOR inhibitors and belatacept.
Diekmann F
Transpl Int; 2015 Aug; 28(8):921-7. PubMed ID: 25959589
[TBL] [Abstract][Full Text] [Related]
9. Impact of mammalian target of rapamycin inhibition on autosomal-dominant polycystic kidney disease.
Wüthrich RP; Kistler AD; Serra AL
Transplant Proc; 2010 Nov; 42(9 Suppl):S44-6. PubMed ID: 21095452
[TBL] [Abstract][Full Text] [Related]
10. Systematic Review on Role of Mammalian Target of Rapamycin Inhibitors as an Alternative to Calcineurin Inhibitors in Renal Transplant: Challenges and Window to Excel.
Kumar J; Bridson JM; Sharma A; Halawa A
Exp Clin Transplant; 2017 Jun; 15(3):241-252. PubMed ID: 27915965
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic Use of mTOR Inhibitors in Renal Diseases: Advances, Drawbacks, and Challenges.
Viana SD; Reis F; Alves R
Oxid Med Cell Longev; 2018; 2018():3693625. PubMed ID: 30510618
[TBL] [Abstract][Full Text] [Related]
12. The pros and the cons of mTOR inhibitors in kidney transplantation.
Ponticelli C
Expert Rev Clin Immunol; 2014 Feb; 10(2):295-305. PubMed ID: 24377908
[TBL] [Abstract][Full Text] [Related]
13. Induction therapy and mTOR inhibition: minimizing calcineurin inhibitor exposure in de novo renal transplant patients.
Nashan B
Clin Transplant; 2013; 27 Suppl 25():16-29. PubMed ID: 23909498
[TBL] [Abstract][Full Text] [Related]
14. Mammalian Target of Rapamycin Inhibitor Monotherapy: Efficacy in Renal Transplantation.
Franco A; Más-Serrano P; Perez Contreras J; Jiménez L; Rodriguez D; Olivares J
Transplant Proc; 2015 Oct; 47(8):2364-7. PubMed ID: 26518928
[TBL] [Abstract][Full Text] [Related]
15. mTOR inhibitors in pancreas transplant: adverse effects and drug-drug interactions.
Fernandes-Silva G; Ivani de Paula M; Rangel ÉB
Expert Opin Drug Metab Toxicol; 2017 Apr; 13(4):367-385. PubMed ID: 27659512
[TBL] [Abstract][Full Text] [Related]
16. mTOR inhibitor-associated proteinuria in kidney transplant recipients.
Diekmann F; Andrés A; Oppenheimer F
Transplant Rev (Orlando); 2012 Jan; 26(1):27-9. PubMed ID: 22137729
[TBL] [Abstract][Full Text] [Related]
17. Safety considerations of mammalian target of rapamycin inhibitors in tuberous sclerosis complex and renal transplantation.
Somers MJ; Paul E
J Clin Pharmacol; 2015 Apr; 55(4):368-76. PubMed ID: 25402866
[TBL] [Abstract][Full Text] [Related]
18. Conversion to mTOR-inhibitors with calcineurin inhibitor elimination or minimization reduces urinary polyomavirus BK load in kidney transplant recipients.
Yen CL; Tian YC; Wu HH; Weng CH; Chen YC; Tu KH; Liu SH; Lee CC; Lai PC; Fang JT; Hung CC; Yang CW; Li YJ
J Formos Med Assoc; 2016 Jul; 115(7):539-46. PubMed ID: 26994751
[TBL] [Abstract][Full Text] [Related]
19. An mTOR-inhibitor-based protocol and calcineurin inhibitor (CNI)-free treatment in kidney transplant recipients from donors after cardiac death: good renal function, but high incidence of conversion to CNI.
Sánchez-Escuredo A; Diekmann F; Revuelta I; Esforzado N; Ricart MJ; Cofán F; Torregrosa JV; Peri L; Ruiz Á; Campistol JM; Oppenheimer F
Transpl Int; 2016 Mar; 29(3):362-8. PubMed ID: 26678359
[TBL] [Abstract][Full Text] [Related]
20. mTOR inhibitors in pediatric kidney transplantation.
Pape L; Ahlenstiel T
Pediatr Nephrol; 2014 Jul; 29(7):1119-29. PubMed ID: 23740036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]